Search Results: 100% Pass Quiz High Pass-Rate Juniper - JN0-281 - Data Center, Associate (JNCIA-DC) New Braindumps Ebook 🐍 Open ➽ www.pdfvce.com 🢪 enter ➡ JN0-281 ️⬅️ and obtain a free download 🔮Valid Exam JN0-281 Book

ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

12/21/2022

Excerpt from the Press Release: SAN MATEO, Calif. and SINGAPORE, Dec. 15, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its TREK-DX study of eblasakimab in adult patients with moderate-to-severe atopic…

Read More

SCDM 2020

09/01/2020

Thank You For Visiting Us From SCDM 2020! Request A Demo, Register For An Event & Learn About Our eClinical Suite We’re so glad you took a few moments of your time to visit us here. SCDM, yet again has produced an incredible event and we’re enjoying the outstanding topics, and of course connecting with…

Read More

Moderna Announces Health Canada Approves its COVID-19 Vaccine

09/21/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years…

Read More

Thermo Fisher Scientific Introduces Highly Sensitive Research Assays for Measurable Residual Disease Detection in Myeloid Malignancies

08/10/2022

Ion Torrent Oncomine Myeloid MRD Assays (RUO) are the first NGS-based tests to offer simultaneous DNA and RNA analysis for myeloid MRD assessment Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific today launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD). As the first NGS-based tests to support…

Read More

Hope Biosciences Stem Cell Research Foundation Selects Phlexglobal to Support Rapid, Compliant Investigational New Drug Application for COVID-19 Therapy

11/19/2020

Excerpt from the Press Release: Phlexglobal, a leading innovative technology and services provider for the life sciences industry, today announces that Hope Biosciences Stem Cell Research Foundation has selected Phlexglobal’s advanced SaaS solution, PhlexSubmission, to enhance the efficiency and quality of its eCTD submissions process. As an organization dedicated to advancing research through innovative protocols…

Read More

CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020

09/01/2020

Excerpt from the Press Release: NEWARK, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced final results from a previously completed open-label Phase 2 study of seladelpar in patients with…

Read More

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval

09/28/2022

Excerpt from the Press Release: FREEMONT, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced enrollment progress in the Phase II Part 2 clinical study of the Company’s ADHD medicine, ABV-1505, currently being conducted at…

Read More

Menon Announces Advancement of Trials on Rapid COVID-19 Test at the University of California San Diego

01/22/2021

Excerpt from the Press Release: SAN DIEGO, Jan. 19, 2021 /PRNewswire/ — Menon Biosensors, Inc. (“Menon” or the “Company”), a distributive technology portfolio company, announced today that trials will advance on its proprietary Molecular Mirror™ platform technology in collaboration with the University of California San Diego School of Medicine (“UC San Diego”) hoping to prove accuracy…

Read More

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

06/30/2022

Excerpt from the Press Release: HAMILTON, ON and BOSTON, June 23, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applications for [225Ac]-FPI-2059 (FPI-2059) and the…

Read More

UConn Geography Researcher Receives Funds to Study Cancer Disparities Among U.S. African Americans

06/08/2023

The study will build upon previous studies conducted by Ghosh and her collaborators that have explored the ways social inequality contribute to unequal cancer control outcomes Excerpt from the Press Release: n January of this year, Debarchana (Debs) Ghosh, associate professor in the Department of Geography in the College of Liberal Arts and Sciences (CLAS)…

Read More